Skip to main content


Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy OnlineFirst articles

24.10.2020 | Invited Review Article Open Access

Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model

Acute heart failure (AHF) is characterized by a gradual or rapid onset of new or worsening signs and symptoms of heart failure (HF), usually requiring hospitalization for urgent therapy. Indeed, AHF is the most common cause for hospital admission …

23.10.2020 | Original Article

Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure

Heart failure (HF) is a worldwide public health concern. Survival after a diagnosis of HF remains quite poor. In particular, the distribution of causes of death is shifted toward non-cardiovascular diseases, underscoring the urgent need for …

22.10.2020 | Original Article

Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective

Myocardial infarction (MI), the most severe manifestation of cardiovascular disease (CVD), is responsible for more than one-third of deaths in developed countries [ 1 ]. It is also the major cause of mortality and chronic disability in China [ 2 ].

21.10.2020 | Invited Review Article Open Access

The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia

Vasoplegia is a complication that occurs in 5–25% of patients that undergo cardiac surgery on cardiopulmonary bypass (CPB) [ 1 , 2 ]. It is defined by profound hypotension, low systemic vascular resistance (SVR), normal or increased cardiac output …

21.10.2020 | Original Article

Overlapping Drug-Eluting Stent Is Associated with Increased Definite Stent Thrombosis and Revascularization: Results from 15,561 Patients in the AUTHENTIC Study

Implantation of a drug-eluting stent (DES) has dramatically reduced the need for revascularization [ 1 ] in patients with obstructive coronary artery disease who underwent percutaneous coronary intervention (PCI). Unfortunately, a comprehensive …

Aktuelle Ausgaben

Über diese Zeitschrift

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

Five Reasons to Publish Your Article in Cardiovascular Drugs and Therapy:

· High usage: Articles frequently downloaded from month to month

· Wide distribution: Institutions worldwide having full text access

· Efficient handling: 18 days between submission and first decision

· Fast publication: 17 days between acceptance and online publication

· International readership: North America, Asia, Europe, Middle East and South America

Weitere Informationen

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.